PUMA BIOTECHNOLOGY, INC.(PBYI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

PUMA BIOTECHNOLOGY, INC. (PBYI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PBYI at 53.8/100 on a 32-signal composite quality model, placing it at rank #1,369 of 2,962 stocks — the top half of the AI-ranked universe. PBYI scores in the top quartile across balance sheet strength (91.5), earnings quality (75.2). Areas of concern include revenue scale (25.7) and institutional flow (34.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), PUMA BIOTECHNOLOGY, INC. reports quarterly revenue of $56.5M, net income of $8.2M, an operating margin of 13.4%. Top institutional holders of PBYI by reported 13-F value include ACORN CAPITAL ADVISORS, BlackRock, AMERICAN CENTURY COMPANIES, based on the most recent SEC filings. PBYI trades on the Nasdaq exchange and files with the SEC under CIK 1401667. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBYI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PUMA BIOTECHNOLOGY, INC. directly from SEC EDGAR.